Hepatitis C Treatment Options


© 2004 All rights reserved.

By joining Find A Cure Panel for people with Hepatitis, you will be empowered to share your opinions in vital research to help find a cure. What's more, for each survey you complete a minimum donation of $25 is made directly to Hepatitis Education And Liver Support on your behalf.

Sulfurzyme is the natural choice to protect and support your liver.

+Promotes proper liver function*
+Supports a healthy immune system*
+Promotes improved liver detoxification*
+Provides important component of Glutathione

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, treat, or prevent any disease.

The Latest News & Research on Hepatitis C and on Hepatitis C Treatment

This webpage specializes in new research on the Hepatitis C Virus and Hepatitis C Treatment
but the information is often relevant to all types of hepatitis and liver disease.

August 2013 Hepatitis C Treatment Research

Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C
This review will describe the potential benefits of combining various DAAs with means to activate the specific immune response against HCV.

July 2013 Hepatitis C Treatment Research

Hepatitis C: New points system helps with disease prognosis
Now a research team led by scientists of the MedUni Vienna has succeeded in developing a points system enabling a better prognosis as to whether the illness will become chronic or whether the acute hepatitis C will spontaneously heal itself.

Interferon-free treatment for genotype-1b hepatitis C patients
Current triple therapies the next generation triple therapies, as well as the future interferon-free treatments, offer shorter treatment duration and higher cure rates.

November 2012 Hepatitis C Treatment Research

Healthy ‘liver friendly’ diet for Hepatitis C sufferers, join Boy George’s C party
Eating well for your liver was the key theme for the dinner and it was my aim to highlight food that is both healthy and delicious.

Gilead lands more strong results from hepatitis C drug study
The hepatitis C virus couldn't be detected in more than three of four patients in a late-stage drug combination trial headlined Gilead Sciences Inc.'s experimental drug sofosbuvir.

Hepatitis C Medicine Trial Shows 100% Cure Rate
Gilead Sciences Inc on Saturday reported a 100 percent cure rate using a combination of drugs in a small number of patients with the most common and hardest to treat form of hepatitis C.

July 2012 Hepatitis C Treatment Research

Hep C Treatment Failure Can Still Mean Less Liver Inflammation
Hepatitis C treatment is typically seen as an all-or-nothing approach—nothing short of a sustained virologic response (SVR), or cure, will benefit people living with the virus. New data, however, suggest that even among those who don’t achieve an SVR, but who do see a substantial drop in hep C viral loads during treatment, there may be a reduction in inflammation associated with liver disease.

June 2012 Hepatitis C Treatment Research

A boomer balancing act: Treat hepatitis C now, or wait?
Dramatic improvements in what is now a very unpleasant drug regimen are expected over the next several years.

Idenix hep C drug shows promise in mid-stage study
Idenix Pharmaceuticals Inc said interim data from a mid-stage trial on its experimental hepatitis C drug showed promise.

April 2012 Hepatitis C Treatment Research

Gilead, Bristol's Hepatitis C Drugs Show Promise In Study
A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study.

Abbott Drugs Suppress Hepatitis C Virus In 2 Studies
Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, midstage studies. The results unveiled Wednesday could reinforce Abbott's position as a key player in an industry race to bring the next generation of drugs to what is expected to be a multibillion-dollar market for hepatitis C therapies. The drugs' safety and efficacy, however, need to be confirmed in additional studies.

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
the second segment of its Phase 2a trial of ACH-1625, 94 to 100 percent of patients with treatment naïve genotype 1 chronic hepatitis C virus (HCV) achieved a complete early virologic response (cEVR) after 12 weeks of treatment with ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R). ACH-1625 in combination with P/R for up to 12 weeks was safe and well tolerated and produced high viral response rates regardless of dose level or IL28B genotype status.

March 2012 Hepatitis C Treatment Research

Prometheus Index Predicts Hepatitis C Treatment Response
In patients monoinfected with hepatitis C virus (HCV), a modification of the Prometheus index reliably estimates the probability of achieving a sustained virologic response with pegylated interferon plus ribavirin therapy, according to research presented here at the 19th Conference on Retroviruses and Opportunistic Infections. This finding, presented at a poster session by José Medrano, MD, a clinical investigator at Hospital Carlos III in Madrid, Spain, could help patients and physicians decide whether to proceed with currently available therapies or to wait for novel therapies that are in development and will likely be available in the near future.

January 2012 Hepatitis C Treatment Research

Cell Permeable Peptide Identified that Inhibits Hepititis C
Researchers from UCLA’s Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication...Considering the potency of the peptide in suppressing viral translation levels, treatment with this peptide may significantly improve the efficacy of conventional treatments in patients who become resistant to conventional therapies.

Stem cells may shed light on hepatitis, MIT researchers find
Researchers at MIT and their colleagues said they have devised a way to produce liver-like cells from stem cells, a key step in studying why people respond differently to Hepatitis C.

Hepatitis C treatment with antivirals is effective: study
A major advance in treating hepatitis C appears to be on the horizon. Researchers reported Wednesday that combining two antiviral medications was effective in stopping the infection in some patients who were not helped by the traditional treatment.

New Therapy for Hep C?
There is no vaccine and no cure for hepatitis C, but researchers at the University of British Columbia believe they have found a new way to block infection from the virus. Our approach would essentially block the life cycle of the virus so that it cannot spread and cause further damage to the liver.

New fibrosis classification improves accuracy of diagnosis in hepatitis C
A new classification for diagnosing fibrosis in patients with chronic hepatitis C virus (HCV) has shown to be as accurate as currently used algorithms, but required no further liver biopsy.

December 2011 Hepatitis C Treatment Research

The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
The green tea molecule, EGCG, potently inhibits HCV entry and could be part of an antiviral strategy aimed at the prevention of HCV reinfection after liver transplantation.

October 2011 Hepatitis C Treatment Research

New drug boosts hepatitis treatment
The new treatment Incivo targets those suffering from genotype 1 hepatitis C, one of the hardest to treat types of the disease.

The Hepatitis C Wars: What Docs Say About The Newest MedsOverall, the main benefit of this new class of hepatitis C treatments is the improvement in sustained viral load or SVR, according to the docs surveyed. While Incivek beat Victrelis on higher SVR, shorter duration and simpler protocol, the perception of superior efficacy was countered by concerns with rash, according to Bio Trends. “While it’s too soon to tell, Victrelis may fill a niche for patients who prefer it’s side effect profile,” the firm reports.

Achillion counts another hep C milestone
New Haven drug developer Achillion Pharmaceuticals Inc. announced Thursday yet another potential one-a-day oral treatment against the highly infectious hepatitis C liver disease.

Achillion said its new candidate, designated ACH-3102, is second-generation treatment that targets and disrupts the blood-borne virus' NS5A gene, neutralizing the germ.

July 2011 Hepatitis C Treatment Research

Raising awareness for hepatitis C July 28 World Hepatitis Day.

Quick Facts about the PI'sIn May 2011 the Food and Drug Administration (FDA) approved the two triple combination HCV protease inhibitor (PI) therapies—Victrelis and Incivek—taken in combination with pegylated interferon and ribavirin. This month I want to concentrate on some of the important information everyone needs to know about the medications to increase the chances of successful treatment and to prevent any possible harm that could result from not taking the medications as prescribed.

June 2011 Hepatitis C Treatment Research

Turkish scientists develop drugs against Hepatitis C Dr. Ercem Atillasoy and Dr. Dalya Guris, Turkish doctors working at Merck Search Laboratory in Pennsylvania, said the medicine they developed against Hepatitis C achieved full treatment of resistant patients. Atillasoy said the medicine called "Protease Inhibitor" got license from FDA in the United States and expected to get license in Europe soon. He said the treatment aims at eliminating the enzyme preventing reproduction of the virus.

New Drug Effectively Treats Hepatitis C The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. Click here to find out more! The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found.

Will new drugs block hepatitis C virus in its tracks? The study by Dr Stephen Griffin and colleagues, published in the journal Hepatology, reveals how two prototype small molecule drugs, known as p7 inhibitors, can each attack different parts of the hepatitis C virus. Their findings suggest that p7 inhibitors could be a powerful way of suppressing hepatitis C, when used together with the latest generation of 'direct-acting' drugs.

Hepatitis study hits upon clue Researchers working to understand the destructive liver disease hepatitis C have made an unexpected discovery that could someday help defeat it.

May 2011 Hepatitis C Treatment Research

The FDA has approved Vertex's Incivek as an add-on to current interferon/ribavirin therapy for hepatitis C infection. Like Victrelis, also approved this month, Incivek greatly boosts the chances that hepatitis C treatment will result in a cure -- that is, a "sustained viral response" or SVR. Incivek and Victrelis both target the HCV protease enzyme, making it nearly impossible for the virus to replicate. Although the virus quickly becomes resistant to either drug used alone, combination therapy with interferon and ribavirin keeps HCV in check.

Hepatitis C drug joins the cocktail party, after a decade of stagnancy. A new hepatitis C drug has come onto the scene — Merck’s boceprevir — after a 10-year lull in HCV therapies entering the market. The FDA’s approval of boceprevir, which will be marketed under the name Victrelis, is a victory for both Merck and HCV patients, as well as for supporters of “cocktail” drug therapies.

April 2011 Hepatitis C Treatment Research

FDA Panel Backs Approval Of Vertex's Hepatitis C Drug Telaprevir
Scripps The panel of non-FDA medical experts voted 18-to-0 on a question that asked whether the available data support approval of the telaprevir in combination with other hepatitis C drugs, pegylated interferon and ribavirin.

Depression May Complicate Hepatitis C Therapy
The study suggests that identifying depression in HCV-infected patients, which is often brought on by interferon (IFN) therapy, and treating it can help boost adherence to therapy.

Hepatitis C treatments could cure disease
Two three-drug regimens appear to cure most people of the most common type of hepatitis C in the U.S. The cocktails consist of two new drugs: boceprevir from Merck & Co. and telaprevir from Vertex Pharmaceuticals. Each is paired with two drugs used to treat hepatitis C for more than a decade — interferon and ribavirin. In the New England Journal of Medicine, Gordon and researchers at 10 U.S. and European centers report that two-thirds of the 403 patients eliminated all traces of the hepatitis C virus, and most sustained that response for as long as six months

March 2011 Hepatitis C Treatment Research

HCV Protease Inhibitor—TMC435: Phase 3 Studies
Tibotec Pharmaceuticals announced that they will begin three different phase 3 studies of their investigational drug TMC435—a once-a-day HCV protease inhibitor (tablet) taken in combination with pegylated interferon and ribavirin. The studies will be guided by type of on-treatment response—12 weeks of triple combination of TMC435/Pegylated interferon/ribavirin followed by an additional 12 or 36 weeks of the combination of pegylated interferon/ribavirin (without TMC435).

February 2011 Hepatitis C Treatment Research

Scripps Health offers genetic testing to patients with Hepatitis C
Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

Researchers develop possible hepatitis C vaccine
A new vaccine being developed by a team of researchers from the University of Copenhagen in Denmark may reduce the number of positive hepatitis C tests in the future. They are reporting one of the first successful trials in inoculating animals against the disease.

Children With Hepatitis C May Benefit From Ribavirin
The combination of pegylated interferon (PEG) plus ribavirin is better than PEG plus placebo for treating children infected with hepatitis C virus, according to a study published in the February issue of Gastroenterology.

January 2011 Hepatitis C Treatment Research

Spotting Gene Variants May Boost Hepatitis C Treatment
Scientists have pinpointed two gene variants that protect hepatitis C patients from anemia caused by antiviral treatment.

UPDATE 1-Vertex Pharma's Hep C drug gets priority review
Priority review status from the FDA reduces the review period by four month, the company said. The same status from Canadian health regulator Health Canada cuts short the review period to six to nine months, compared to a review period of 18 months or more.

Hepatitis C hope for Baby Boomers and others
Two powerful drugs are nearing the market that promise to help cure those suffering from the more people of liver-attacking virus.

December 2010 Hepatitis C Treatment Research

Vertex Ends Part of Telaprevir Study for Hepatitis C
Vertex is halting a test of its medicine telaprevir in combination with its other experimental therapy called VX-222, the Cambridge, Massachusetts-based company said in a statement. Vertex will continue testing telaprevir and VX-222 in groups of patients who will receive it with one or two drugs given as a combination treatment.

Idera Pharmaceuticals Announces Preliminary Data from Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients
n the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment. IMO-2125 is a Toll-like Receptor 9 (TLR9) agonist which stimulates production of natural interferons and other antiviral cytokines.

Coffee Slows Progression of Hep C Liver Disease
People living with chronic hepatitis C virus (HCV) infection and advanced liver disease who drink three or more cups of coffee per day have a 53 percent lower risk of liver disease progression than non-coffee drinkers, according to a new study published in the November issue of Hepatology.

Potential new target for hepatitis C drug development identified
This new finding by researchers from the Florida campus of The Scripps Research Institute strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

November 2010 Hepatitis C Research

Hepatitis C Vaccine Elicits Immune Response in Some Patients
A therapeutic vaccine against the hepatitis C virus was associated with a significantly higher sustained virologic response rate when added to standard-of-care treatment, and the findings justify further development of the vaccine, Dr. Paul Pockros reported at the annual meeting of the American Association for the Study of Liver Diseases.

Vertex submits application for hepatitis C drug
Vertex Pharmaceuticals Inc. said today that it has completed the submission of a New Drug Application that seeks regulatory approval for telaprevir, a hepatitis C drug candidate with the potential to generate billions of dollars in annual revenue.

Medivir Gains as Early Study Shows Drug Kills Hepatitis C Virus
Medivir AB, the drugmaker competing to develop a new hepatitis C medicine, rose the most in four months in Stockholm trading after its drug reduced the virus to undetectable levels in patients who failed earlier treatment.

A New Era of Hepatitis C Therapy: AASLD 2010
In summary, these exciting data suggest that we have already entered or will shortly enter the new and exciting area of personalized medicine in treatment of hepatitis C patients by using response-guided therapy, IL-28B biomarkers, and once approved, regimens that would include targeted therapy with triple regimens that include protease inhibitors.

October 2010 Hepatitis C Research

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.
In recent years, the recommendation to treat hepatitis C virus genotype 2- and 3-infected patients with a fixed 800 mg/day dose of ribavirin in combination with PEG-IFN and for just 24 weeks has been challenged by the concept of tailoring the length of therapy according to on-treatment viral response.

Race Affects Hepatitis C Recurrence After Liver Transplant
Hepatitis C patients who receive a liver from a white donor have significantly more aggressive recurrent hepatitis than those who receive a liver from a black donor, researchers have found.

Roche hepatitis C drug appears safe in combination
Our study was to combine two different drugs with two different mechanisms of action; they target different parts of the virus. We wanted to see if we can prevent emergence of resistance and suppress the virus and this is certainly what was shown. There were no cases of resistance in this study.

September 2010 Hepatitis C Research

Vertex hepatitis C drug helps the hard-to-treat
Vertex said 65 percent of patients who were treated with a drug cocktail including telaprevir were cured, meaning the hepatitis C virus could not be detected in their bodies. That compares with just 17 percent of patients who were treated with only the drugs pegylated interferon and ribavirin.

Hepatitis C Virus Faces New Weapon From Scientists
The CoFIM screening method involves inducing or “coaxing” the HCV virus to mutate by itself, in vitro, absent the replication assistance it normally receives from a particular cellular cofactor. Then, CoFIM tracks the changes in the virus’s response both to CsA-based drugs and any other drug designed to inhibit the cofactor.

Taribavirin Shows Benefit in Hepatitis C Versus Ribavirin
Taribavirin appears to be a safe and effective alternative to ribavirin for treating chronic hepatitis C, with lower associated rates of anemia, according to research published in the Hepatology.

August 2010 Hepatitis C Research

Experimental antiviral drug boceprevir doubles cure rate for hepatitis C
An experimental antiviral agent called boceprevir doubled the cure rate for hepatitis C in a small phase 2 clinical trial designed to show efficacy, researchers reported Sunday. The drug will now be submitted to the larger Phase 3 trial required for approval of the drug by the Food and Drug Administration.

Vertex: telaprevir could shorten hep C treatment
Vertex said patients who responded quickly to treatment with telaprevir had better results after 24 weeks of therapy than after 48 weeks. The company said that shows a 24-week regimen including telaprevir can be an effective treatment for the disease.

July 2010 Hepatitis C Research

Hope Against Hepatitis C
Robust new therapies against hepatitis C virus could begin reaching the market as early as next year, and two protease inhibitors are top candidates.

Hepatitis C Treatments in Current Clinical Development
There are many compounds being studied to treat hepatitis C. Every effort has been made to focus this list only on treatments that are known to be in current or very near to active clinical development in human subjects.

June 2010 Hepatitis C Research

Making Friends with Fatigue
Since fatigue is a tough problem to overcome, it can be difficult to figure out where to start. I am going to share some strategies that helped to get me started.

Hepatitis C-related virus in Asian bats could cut human infections
A virus related to hepatitis C, found in Asian bats, could offer insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans, according to researchers.

Hepatitis C Increases Risk Of Type 2 Diabetes
Dietary changes can help signicantly in reducing the risk of damage to your liver and can control your type 2 diabetes.

May 2010 Hepatitis C Research

Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis.
The morbidity and mortality of chronic hepatitis C is related to progressive fibrosis and the development of cirrhosis. The development of fibrosis in patients with HCV is highly influenced by immune status, host response to the virus and associated factors, such as, age, sex, alcohol intake, diabetes, obesity and coinfection with other viruses. The rate of fibrosis progression differs depending on several factors, including the stage of fibrosis and the time since infection. Routine assessment of fibrosis through biopsy every 3-5 years has poor patient acceptance and reliability, and might result in missed opportunities to improve or modify treatment priorities. Enhanced understanding of the pathophysiology of liver fibrosis in HCV infection has led to the development of a number of non-invasive assessment modalities.

A Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication.
Clearance studies using replicon cells demonstrated that PSI-7851 was able to clear cells of HCV replicon RNA and prevent viral rebound.

Hepatitis C Drug Telaprevir Raises Cure Rate
Adding the experimental hepatitis C drug telaprevir to standard interferon/ribavirin therapy cured 75% of newly treated patients, drug maker Vertex announced.

April 2010 Hepatitis C Research

Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods
Approximately 30% of patients with null-low fibrosis may be accurately identified by supplementing current scores with new independent variables (serum ferritin and cholesterol), thus obviating the need for a liver biopsy.

Experimental Drug May Treat Hepatitis C
In preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.

Pharmasset hep C drug shows efficacy in mid-stage trial
Pharmasset Inc (VRUS.O) said a mid-stage study of its experimental hepatitis C treatment showed the drug had short-term antiviral activity and was safe and well tolerated.

Combination of direct antivirals may be key to curing hepatitis C
A combination of antiviral drugs may be needed to combat the drug resistance that rapidly develops in potentially deadly hepatitis C infections, a new study using sophisticated computer and mathematical modeling has shown.

March 2010 Hepatitis C Research

Human Genome hep C drug shows promise in mid stage.
Human Genome Sciences Inc (HGSI.O) said interim data from a mid-stage study testing a monthly-dosing version of its experimental hepatitis C treatment, Zalbin, showed the drug's efficacy was comparable with the current standard of care.

Potential new target for treating Hepatitis C found
Binding of Isis-11 resulted in a major conformational change in a specific region of HCV RNA that is thought to be critical for viral replication," says Davis. "This alteration in structure provides a possible mechanism for the antiviral activity of Isis-11 and other HCV replication inhibitors in that chemical class.>

Researchers explore hepatitis C-diabetes link
Australian researchers are studying the link between Hepatitis C and the development of diabetes and they have made an unexpected discovery. Initially, the increase risk of type 2 diabetes was thought to be associated with fat build-up in the liver caused by Hepatitis C but tests on people with blood-borne virus was something different. In a study of 29 participants who had "high insulin resistance" a precursor to diabetes, by the Garvan Instituted of Medical Research found that the problem was rooted in the muscles and not the livers.>

February Hepatitis C Research

The Institute of Medicine (IOM) report on a national strategy for the prevention and control of hepatitis B and C.
The report detailed many recommendations for the control and prevention of viral hepatitis in this country. ?record_id=12793

HCV Drug Resistance
A new approach to hepatitis C treatment – specifically targeted antiviral therapy for hepatitis C, or “STAT-C” – promises to improve the likelihood of achieving a cure for hard-to-treat patients. But these new therapies also come with a drawback: HCV can develop drug resistance, making them less effective.

Role of Sleep Disturbance in Chronic Hepatitis C Infection.
Evidence suggests that impairments in sleep quality exist independent of antiviral therapy with interferon-alpha and prior to advanced stages of liver disease. Further investigation of sleep disturbance in CHC patients with a mild stage of liver disease may provide important information on disease course as well as allow additional opportunities for patient support.

January Hepatitis C Research

New research finds promising treatment for hepatitis C
US scientists have discovered a way to block replication of the hepatitis C virus, potentially leading to better treatment for the top cause of liver cancer in the United States, a study said Wednesday. Glenn foresees a year to 18 months of preclinical and animal testing before the Food and Drug Administration (FDA) can approve the class of compounds for clinical trials in humans.

Dynavax hepatitis C drug shows promise in phase 1 trial
The early-stage trial evaluated four dose levels of the drug, SD-101, in 34 chronically infected, treatment-naive hepatitis C patients, and showed all the patients at the highest dose experienced a reduction in viral load, or the severity of the viral infection. Dynavax also posted the results from an in-vitro study of the drug's mechanism of action in human blood cells.

Coffee Cuts Liver Scarring in Hepatitis C
Caffeine in coffee reduces the severity of liver fibrosis in patients with chronic hepatitis C virus, a new study has found. Other sources of caffeine don't have same effect, study shows.I postulate that this is because coffee reduces the size of gall bladder stones and frees them to get out and that liver cleanses could have the same effect without the caffine. Just my theory though!

December 2009 Hepatitis C Research

Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Preliminary results showed that a mean reduction in viral load of 3.94 log10 was achieved in the treatment group, as compared to a mean reduction of 0.22 log10 in the placebo group. All subjects in the treatment group had viral load decline between 3.0 and 4.5 log10, and two subjects reached undetectable levels of HCV RNA. Furthermore, all patients had viral loads that remained suppressed for at least 7 days after dosing was completed, maintaining a mean reduction of more than 2.0 log10 from baseline through day 12, the last day of viral load measurement in the study.

Hepatitis C drug shows positive results in trial
Its experimental hepatitis C drug is meeting key goals in a midstage clinical trial, Anadys Pharmaceuticals Inc. announced on Thursday. The company said in a combination treatment 56 per cent of the patients receiving the ANA598 showed undetectable levels of the virus at four weeks, compared to others who totaled 20 percent of patients who received the replica drug.

Experimental drug is combating hepatitis C in chimps, researchers say The antiviral, which is already being tested for safety in humans, has exhibited no toxic side effects and has not allowed development of resistance, a characteristic that plagues other treatments.

Researchers develop new hepatitis C treatment
The treatment, dubbed SPC3649, works by inhibiting a molecule that helps hepatitis C virus replicate, according to scientists at the Southwest Foundation for Biomedical Research (SFBR), who said the drug continued to work up to several months after it was used. This antiviral could be used alone to treat disease progression and there are indications that it can convert interferon non-responders to responders, so that non-responders to the current therapy could be treated with the combination of this drug with interferon.

November 2009 Hepatitis C Research

Tripep: The ChronVac-C(R) Study Has Been Successfully Completed With Good Safety And Favorable Clinical Data
Early data from three patients who have initiated standard of care treatment after completing the clinical trial have experienced a rapid loss of the virus, implying a possible role for ChronVac-C® in combination therapies. Tripep will therefore pursue clinical development of ChronVac-C® along two lines, the current ChronVac-C® as an addition to standard of care, and a 2nd generation improved ChronVac-C® as a monotherapy. GMP production and preclinical safety testing of the 2nd generation ChronVac-C® should start in the spring of 2010.

Role of free radicals in liver diseases.
Reactive oxygen and nitrogen species (ROS and RNS) are produced by metabolism of normal cells. However, in liver diseases, redox is increased thereby damaging the hepatic tissue. The common mechanism for hepatocarcinogenesis (cause of liver cancer) is chronic inflammation associated with severe oxidative stress. As a consequence, antioxidants have been proposed as an adjunct therapy for various liver diseases.
PMID: 19941170

Vitamin D Boosts Treatment of Chronic Hepatitis C
Adding a daily dose of Vitamin D to the regimen of pegylated interferon-alfa 2 and ribavirin might increase the response rates, according to an abstract which was presented at the Liver Meeting 2009, the 60th Annual Meeting of the American Association of the Study of Liver Disease.

Multitasking may be Achilles heel for hepatitis C
The virus is a microcosm of efficiency, and each of its amino acids plays multiple roles in its survival and ability to sidestep attack. But new research from Rockefeller University suggests that this fancy footwork and multitasking could be the key to bringing down the virus. The work, which focuses on a once-ignored protein, provides insights on how drug therapy for sufferers of the disease might be improved.;=1001

The Antifibrotic Effects Of Green Tea
The researchers drew a conclusion that green tea may protect liver cells and reduce the deposition of collagen fibers in the liver. Green tea provides a safe and effective strategy for improving hepatic fibrosis.

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.
PMID: 19918980

Boceprevir Study Doubles Hepatitis C Clearance Rate
The triple combination of boceprevir and the current treatments of pegylated-interferon and ribavirin appears to eliminate the virus at double the rate of the standard drugs alone.\BNCFB00

Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis.
PMID: 19902019

Doc Offers Top Hep C Drug Picks
Respected doctor's opinion on the hits and misses coming from last week's annual meeting of the American Association for the Study of Liver Disease.

What Is the Optimal Timing of Hepatitis C Antiviral Therapy Before and After Liver Transplantation?
Treatment of patients with compensated cirrhosis was the most cost-effective strategy; it resulted in improved survival and decreased cost when compared with the other 3 strategies. Given these results, we strongly recommend expeditious administration of antiviral therapy to patients with compensated cirrhosis before their disease advances.

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study
It is believed that taribavirin (TBV) may present an alternative therapy to ribavirin (RBV) for the treatment of hepatitis C by delivering similar efficacy to ribavirin but with significantly less anemia, which is the main treatment-limiting toxicity associated with ribavirin.

Diet and Hepatitis C
Today, hepatology experts increasingly recognize the importance of the metabolic aspects of chronic hepatitis C, and pay more attention to managing obesity and blood sugar and fat abnormalities.

UPDATE 1-Once-daily Schering hepatitis C drug shows promise
85-87 pct have no trace of virus after 12 wks; Side effects similar to standard 2-drug combo

Twice Daily Oral Medication Shows Promise in Treating Patients with Hepatitis C
This is the first study to demonstrate that an IFN-free, twice daily, combination DAA regimen produces similar antiviral activity compared to triple therapy (SOC plus protease) over 2 weeks of treatment," said Dr. Gane. "This combination may represent the first IFN-free treatment regimen for both treatment-naive and previously treated patients with HCV Genotype 1 infection.

GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15%

Schering-Plough reports data on hepatitis C drug
Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.\BNCFB00

October 2009 Hepatitis C Research

The Relationship Between Hepatitis C and Vascular Disease
Mixed cryoglobulinemia is a common extrahepatic manifestation of Hepatitis C. Although not much is known about why this vascular disease frequently accompanies the Hepatitis C virus, researchers have uncovered some new information.

Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
Today, Idenix announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in Boston, Massachusetts.

NVHR Applauds New Bipartisan Legislation
Bipartisan legislation introduced today in the US House of Representatives, "The Viral Hepatitis and Liver Cancer Control Act," will increase awareness and prevention of a disease that is already afflicting over 5 million Americans - more than half of whom do not know they are infected - and will help set the stage to avoid tens of billions of dollars in unnecessary health care costs in the coming decade, the National Viral Hepatitis Roundtable (NVHR) said today.

ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb
PEG-Interferon lambda (IL-29) is a novel type 3 interferon in development for hepatitis C. The native human protein Interferon lambda is generated by the immune system in response to viral infection. In a Phase 1b clinical trial in patients with relapsed HCV, administration of PEG-Interferon lambda over four weeks in combination with ribavirin was shown to be well-tolerated and resulted in significant antiviral activity.

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
This case suggests that long-term telaprevir monotherapy may be effective in CH-C patients with genotype 1 and a low viral load.
PMID: 19857995

Vertex hep C drug helps tough to treat patients
Interim results from an ongoing study released on Wednesday showed that 57 percent of patients, who failed to respond to treatment with the standard treatments of pegylated-interferon and ribavirin and 90 percent of those who responded but later relapsed, achieved a sustained viral response when telaprevir was added to their regimen.

Hepatitis C Personal Stories
New Webpage created for sharing personal experiences with the Hep C virus.

SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
SciClone is eager to investigate further SCV-07's potential to enhance the immune response against hepatitis C and to determine whether the compound is capable of improving the current standard of care treatment.

New Book, 'Breaking Free from Hepatitis C: A Personal Journey'
Personal account, based on author's journal and experience over the course of 11 years, offers insider's look and calls for action on prevention.

Lots of coffee may be good for people with hepatitis C
A study of people infected with the liver-damaging virus hepatitis C found the risk of serious liver damage halved in people who drank at least three cups of coffee a day.

Hepatitis C and Alcohol
Is it okay to have an occasional drink if you have Hepatitis C?

Human Genome Sciences gets milestone payment for development of hepatitis C drug, Zalbin
Human Genome Sciences Inc. said Monday it will be paid $75 million by Swiss drugmaker Novartis AG for successful clinical testing of the hepatitis C drug candidate Zalbin. The companies plan to file for U.S. and European regulatory approval in the fourth quarter. Assuming licensure by the FDA and other regulatory agencies, HGS believes that ZALBIN could become a market-leading treatment for chronic hepatitis C.

Hepatitis C Associated Skin Conditions
Review of Hep C associated skin problems by the Society of Correctional Physicians (SCP).

Liver stiffness scan shows cirrhosis
Fibroscan is a quick and reliable noninvasive technique that can be applied successfully in the vast majority of patients to estimate liver fibrosis. The commonest indication for Fibroscan is chronic hepatitis C.

Aethlon Medical Announces BIOCOM Conference Presentation
Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes.

Researchers Pave The Way For Effective Liver Treatments
This will give us new insights for the treatment for liver fibrosis, and it will give us the platform to test new treatments. This also allows us to do the critical experiments that will assess the ability of different drugs to work. There are really no effective therapies for liver fibrosis—there is only transplantation. Any less invasive therapy would be desirable. This is a big advance.

Liver Cells Grown From Patients' Skin Cells
It is possible that in the future a small piece of skin from a patient with loss of liver function could be used to produce healthy liver cells, replacing the diseased liver with normal tissue.

Treatment optimization in chronic hepatitis C virus infection
The treatment duration that obtains the optimal risk-benefit ratio in chronic hepatitis C infection is guided by viral kinetic data in weeks 4 and 12.
PMID: 19804920

7 Ways to Manage the Stress of Living with Hepatitis C
Expert Physician Offers Coping Strategies and Much More in New Book Edition. "We don't choose to be sick, but we can choose how we try to handle the situation." Living with Hepatitis C, Fifth Edition;=14

Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus
The data showed that AVL-181 bonds selectively, covalently and irreversibly to HCV protease (also known as "NS3/4A"), thus silencing a key protein necessary for successful viral replication resulting in a prolonged duration of action. Furthermore, the data demonstrate that the amount of HCV protease silenced by AVL-181 can be measured in a dose- and time-dependent manner in an animal model using Avila's novel translational technology known as a covalent probe.;=20091\005005164&newsLang;=en

Keeping hepatitis C virus at bay after a liver transplant
One of the most common reasons for needing a liver transplant is liver failure or liver cancer caused by liver cell infection with hepatitis C virus (HCV). However, in nearly all patients the new liver becomes infected with HCV almost immediately. But now, Hideki Ohdan, Kazuaki Chayama, and colleagues, at Hiroshima University, Japan, have developed an approach that transiently keeps HCV levels down in most treated HCV-infected patients receiving a new liver.

Top 10 Post Counseling Messages
Messages we can give to advise the newly diagnosed person during this difficult period.

September 2009 Hepatitis C Research

Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting
Patients with CHCV genotype 1 infection should be treated with PEG-IFN plus ribavirin combination therapy as early as possible, and 72 weeks' treatment is recommended in patients with LVR regardless of age.
PMID: 19788694

Silymarin Inhibits in Vitro T Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection.
Silymarin's (an extract of milk thistle) ability to inhibit the proliferation and pro-inflammatory cytokine secretion of T cells, combined with its previously described anti-viral effect suggests a possible mechanism of action that could lead to clinical benefit during HCV infection.
PMID: 19782083

Should Those With Hepatitis C Get a Swine Flu Shot?
In and of itself, Hepatitis C does not imply a mandatory H1N1 vaccination. Some of the indicators of a high swine flu complication risk are age, chronic disease, diabetes, immune system strength and being overweight. There are some with Hepatitis C who are strong, have no detectable liver damage and are able to fight off pathogens. These individuals may opt to focus on lifestyle practices to stay healthy instead of receiving a shot.

Marcial: Pharma Firms May Vie for Vertex
Telaprevir is a potential blockbuster drug for treating hepatitis C, with a multibillion-dollar market. Vertex could get FDA approval for it next year.

Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients
ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. We are pleased that the outstanding safety profile established in preclinical testing continues to be seen in this human clinical trial.

Smoking Pipes May Transmit HCV
New research shows that a pipe passed between people is capable of transmitting the Hepatitis C infection.

Can Vitamin B-12 Help Hepatitis-Related Fatigue?
Although there are only a few reasons that someone with hepatitis could benefit from vitamin B-12 for an energy boost (anemia,alcohol, Encephalopathy, aged over 60), there is some interesting evidence tying this nutrient to Hepatitis C suppression.

Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial.
We aimed to investigate whether blood letting improves the efficacy (SVR) and tolerability of PEG-IFNalpha2b + Ribavirin in chronic hepatitis C patients. They conclude that blood letting does not increase the overall efficacy of antiviral therapy. However, there was a strong trend to higher sustatined viral remission SVR in naive patients undergoing phlebotomies (blood lettings) and this warrants further investigation.
PMID: 19760753

Blueberries, Asparagus and HCV
Being a lover of blueberries and asparagus, the recent news articles about research done on blueberries and HCV and asparagus and liver toxicity not only got my interest but also perked up my appetite!

Genetic Hint for Ridding the Body of Hepatitis C
30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.;=12%\ 2026%20PDT&year;=2009&public;=0

New Collaborations and Breakthrough Advancements in RNA-Based Drug Development
Advancing the first microRNA therapy for Hepatitis C into human clinical trials.

Managing depression during hepatitis C treatment.
Mental illness, particularly depression, is common among HCV-infected patients and remains an obstacle to interferon-alpha (IFN-alpha) treatment. We summarize the risk factors for interferon-alpha-induced major depressive disorder (IFN-alpha-MDD) in HCV patients and the evidence for antidepressant prophylaxis and symptomatic antidepressant treatment of depression.
PMID: 19751550

Clinical Trials of New Anti-Hepatitis C Drug Began
Russian medics and engineers report about finishing preclinical trial stage of a new candidate drug for treating hepatitis C and starting clinical trials. The ID-12 chemical compound is an original low molecular inhibitor, which blocks initial stages of virus expansion.

Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.
PMID: 19748329

Aussies aid Hepatitis C 'breakthrough'
Very exciting new research:
"...researchers said the new study showed use of the interferon-lambda in treatment could benefit those people identified as best suited to receive it and spare others the cost and side effects of their current treatments." That would be nice! rough-20090914-fmdz.html

Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C.
The results of this study provide additional evidence that obesity worsens liver damage in patients with chronic hepatitis C, and suggest a role for weight loss as a treatment modality in these patients.
PMID: 19745689

MSM as a Liver Supplement for those with Hepatitis C
MSM may be useful to avoiding and repairing fibrosis of the liver.

Retreatment Benefits Some Hepatitis C Non-Responders
The author found that 48 weeks of retreatment with pegylated interferon alfa plus ribavirin resulted in sustained virologic response in 10 to 20 percent of patients who previously failed standard treatment and in 6 to 8 percent of those who previously failed a course of pegylated interferon alfa plus ribavirin. He also found that 72 weeks of retreatment was associated with higher rates of sustained virologic response, and that long-term, low-dose interferon-based maintenance treatment had no significant effect on clinical outcomes.

Largest comparative hepatitis C study confirms treatment effectiveness and lower relapse rate for Pegetron(R) patients
A noteworthy finding is that patients receiving the peginterferon alfa-2b and ribavirin (Pegetron) treatment regimen were significantly less likely to relapse than those receiving Pegasys RBV. Lower relapse rates are important for patients because the side effects of hepatitis C treatments can be quite debilitating. Another important finding from the study was the confirmation of early responses to treatment exhibited among patients as an indication of overall success.

Physician Congressman Speaks Up on Viral Hepatitis
The National Viral Hepatitis Roundtable (NVHR) is hosting a briefing, The Experts' Perspective: Gaps and Strategies in the Hepatitis Crisis. -hepatitis,952475.shtml

Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
ANA598 has demonstrated potent antiviral activity and good tolerability as a single agent, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens. HIV/HCV Coinfection Updates from the International AIDS Society Conference

Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.
AHC remains rare, and drug and sexual transmission are predominant. A 3-month follow-up after diagnosis avoids treatment for four out of 10 patients. Antiviral treatment is highly effective, 24 weeks of pegylated interferon-alpha alone being a good option.
PMID: 19734798

Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection.
Food intake increases liver stiffness in patients with hepatitis C virus infection and healthy controls. To standardize liver stiffness evaluation, we suggest measurement in the fasting condition.
PMID: 19732330

Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C.
Clinical progression of chronic hepatitis C depends on several cofactors, which also have a negative affect on the rate of response to interferon-alpha-based therapy.
PMID: 19732324

Nutritional Healing for Hepatitis C
Everyone with Hepatitis C, also known as HCV, should take an active part in the maintenance of their health and treatment of their disease with the guidance of a qualified health care professional. The more we learn about nutrition and how it may help improve our condition or assist in treating HCV, the better prepared we will be to take an active role in our Hep C treatment. Read more including diet tips.

A Review of Sleep Disturbance in Hepatitis C. PMID: 19730115

RNAi as a new therapeutic strategy against HCV.
Several reports have indicated the efficiency and specificity of synthetic and vector based siRNAs inhibiting HCV replication. In the present review, we focused on the recent development in the potential use and issues regarding siRNA as a therapy for HCV.
PMID: 19729057

Brand new interview with Dr. Zhang on Hepatitis C Treatment
Interview with author of, "Healing Hepatitis C with Modern Chinese Medicine"

Hepatitis C therapy-the future looks bright.
Over the past three decades, ribavirin and interferon-alpha have remained the only available medicines for treating hepatitis C sufferers. Given that this combination therapy is partially effective at best and is associated with severe side-effects, there is an unmet need for new molecular entities which inhibit HCV replication. By employing a combination of structure-based drug design together with high-throughput screening approaches, several pharmaceutical companies have been successful in identifying potentially useful compounds for treating HCV infections. This article provides an overview of some of the small-molecule inhibitors that have shown promise so far in clinical trials and which could reach the clinic within the next three years.
PMID: 19727870

Blueberry leaves can help fight against hepatitis C, according to a new study.
According to scientist Hiroaki Kataoka and colleagues, a chemical found in rabbit-eye blueberry, found in the southeastern regions of the US, strongly suppressed replication of the hepatitis C virus. The blueberry leaf-derived viral replication inhibitor was found to be proanthocyanidin.